INS and Hypoglycemia: The GLP-1 receptor agonist liraglutide (lira) has been shown in clinical studies outside Japan to significantly decrease HbA1c compared with glimepiride, inhibit weight gain, decrease the risk of hypoglycemia [4] and, in combination with oral hypoglycemic agents, to powerfully improve blood glucose compared with sustained-release insulin [5].